Brought to you by:
CIRSE begins CALCIO trial enrolment for treatment of CLTI with Shockwave IVL system
The Cardiovascular and Interventional Society of Europe (CIRSE) have announced that patient enrolment for the CALCIO trial has begun. CALCIO started patient enrolment on 15 July, 2024, with the goal of recruiting 400 chronic limb-threatening ischaemia (CLTI) patients over the…
LimFlow announces agreement to be acquired by Inari Medical
LimFlow announced today that it has entered into a definitive agreement to be acquired by Inari Medical. A press release details that, under the terms of the agreement, LimFlow will receive US$250 million in cash at closing and be eligible…
Insights from largest chronic limb-threatening ischaemia study to inform quality of care improvements
Data from a cohort of one million patients with chronic limb-threatening ischaemia (CLTI) were recently presented as late-breaking clinical research at the Society for Cardiovascular Angiography & Interventions (SCAI) 2023 Scientific Sessions (18–20 May, Phoenix, USA). Using data from Medicare, the…
New analysis of chronic limb-threatening ischaemia patients places BEST-CLI trial into context within real-world setting
A new analysis of chronic limb-threatening ischaemia (CLTI) treatment outcomes was presented today as late-breaking clinical research at the Society for Cardiovascular Angiography & Interventions (SCAI) 2023 Scientific Sessions (18–20 May, Phoenix, USA), a press release reports. Following the initial…
BioGenCell begins recruitment for clinical trial of stem cell-based treatment for preventing limb amputation
BioGenCell has announced that it is recruiting for an international clinical trial to assess the company’s stem cell-based therapy for chronic limb-threatening ischemia patients who are at risk for limb amputation. The clinical trial is currently taking place in medical…
First data from BEST-CLI bring surgical bypass into the forefront of discussion for patients with high-quality great saphenous vein
The first results from the BEST-CLI randomized controlled trial (RCT) of 1,830 patients show that surgical bypass with adequate single-segment great saphenous vein (GSV) is a more effective revascularization strategy for patients with chronic limb-threatening ischemia (CLTI) who are deemed…